Global Viral Partnering 2010-2016: Deal trends, players and financials

Published: November 2016
No. of Pages: 500
    ReportsandReports

“Delivery of this report will take 1-3 days after purchase.”

Global Viral Partnering 2010 to 2016 provides the full collection of Viral disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.

Trends in Viral partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Viral partnering agreement structure
Viral partnering contract documents
Top Viral deals by value
Most active Viral dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Viral disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Viral deals.

The report presents financial deal terms values for Viral deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Viral dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Viral dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Viral deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Viral dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Viral deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Viral partnering deals by specific Viral target announced since 2010. The chapter is organized by specific Viral therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Viral partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Viral partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Viral technologies and products.

Report scope

Global Viral Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Viral trends and structure of deals entered into by leading companies worldwide.

Global Viral Partnering 2010 to 2016 includes:

Trends in Viral dealmaking in the biopharma industry since 2010
Analysis of Viral deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Viral deal contract documents
Comprehensive access to over 3500 Viral deal records
The leading Viral deals by value since 2010
Most active Viral dealmakers since 2010

The report includes deals for the following indications:
Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.

In Global Viral Partnering 2010 to 2016, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Viral Partnering 2010 to 2016 report provides comprehensive access to available deals and contract documents for over 1,500 viral deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise viral rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Global Viral Partnering 2010 to 2016 provides the reader with the following key benefits:

In-depth understanding of Viral deal trends since 2010
Access Viral deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Viral partner companies
Comprehensive access to over 750 links to actual Viral deals entered into by the world’s biopharma companies
Indepth review of Viral deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Viral opportunities
Uncover companies actively partnering Viral opportunities

Published By: Current Partnering
Product Code: Current Partnering556


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:

  • Europe Glimepiride Market Report 2016

    Notes: Sales, means the sales volume of Glimepiride Revenue, means the sales value of Glimepiride This report studies sales (consumption) of Glimepiride in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focus...

  • Europe Dolutegravir Market Report 2016

    Notes: Sales, means the sales volume of Dolutegravir Revenue, means the sales value of Dolutegravir This report studies sales (consumption) of Dolutegravir in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, fo...

  • Global Penicillin Market Professional Survey Report 2016

    Notes: Production, means the output of Penicillin Revenue, means the sales value of Penicillin This report studies Penicillin in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue...

  • Global Letrozole Market Professional Survey Report 2016

    Notes: Production, means the output of Letrozole Revenue, means the sales value of Letrozole This report studies Letrozole in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, c...

  • United States Sea Cucumber Capsule Market Report 2016

    Notes: Sales, means the sales volume of Sea Cucumber Capsule Revenue, means the sales value of Sea Cucumber Capsule This report studies sales (consumption) of Sea Cucumber Capsule in United States market, focuses on the top players, with sales, ...

  • Global Indomethacin Market Professional Survey Report 2016

    Notes: Production, means the output of Indomethacin Revenue, means the sales value of Indomethacin This report studies Indomethacin in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, r...

  • United States Veterinary Drugs Market Report 2016

    Notes: Sales, means the sales volume of Veterinary Drugs Revenue, means the sales value of Veterinary Drugs This report studies sales (consumption) of Veterinary Drugs in United States market, focuses on the top players, with sales, price, reven...

  • United States, EU, Japan, China, India and Southeast Asia Tuberculosis Testing Market Size, Status and Forecast 2021

    Notes: Production, means the output of Tuberculosis Testing Revenue, means the sales value of Tuberculosis Testing This report studies the global Tuberculosis Testing market, analyzes and researches the Tuberculosis Testing development status an...

  • United States Alopecia Drugs Market Report 2016

    Notes: Sales, means the sales volume of Alopecia Drugs Revenue, means the sales value of Alopecia Drugs This report studies sales (consumption) of Alopecia Drugs in United States market, focuses on the top players, with sales, price, revenue and...

  • Europe Intravenous Solution Market Report 2016

    Notes: Sales, means the sales volume of Intravenous Solution Revenue, means the sales value of Intravenous Solution This report studies sales (consumption) of Intravenous Solution in Europe market, especially in Germany, UK, France, Russia, Ital...


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: